These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [11C]flumazenil PET: activity images versus parametric images for the detection of neocortical epileptic foci. Niimura K; Muzik O; Chugani DC; Shen C; Chugani HT J Nucl Med; 1999 Dec; 40(12):1985-91. PubMed ID: 10616875 [TBL] [Abstract][Full Text] [Related]
10. [11C]Flumazenil PET in patients with epilepsy with dual pathology. Juhász C; Nagy F; Muzik O; Watson C; Shah J; Chugani HT Epilepsia; 1999 May; 40(5):566-74. PubMed ID: 10386525 [TBL] [Abstract][Full Text] [Related]
11. Is 11C-flumazenil PET superior to 18FDG PET and 123I-iomazenil SPECT in presurgical evaluation of temporal lobe epilepsy? Debets RM; Sadzot B; van Isselt JW; Brekelmans GJ; Meiners LC; van Huffelen AO; Franck G; van Veelen CW J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):141-50. PubMed ID: 9048714 [TBL] [Abstract][Full Text] [Related]
12. [11C]Flumazenil PET in temporal lobe epilepsy: do we need an arterial input function or kinetic modeling? Hammers A; Panagoda P; Heckemann RA; Kelsch W; Turkheimer FE; Brooks DJ; Duncan JS; Koepp MJ J Cereb Blood Flow Metab; 2008 Jan; 28(1):207-16. PubMed ID: 17579659 [TBL] [Abstract][Full Text] [Related]
13. 18F-flumazenil: a γ-aminobutyric acid A-specific PET radiotracer for the localization of drug-resistant temporal lobe epilepsy. Vivash L; Gregoire MC; Lau EW; Ware RE; Binns D; Roselt P; Bouilleret V; Myers DE; Cook MJ; Hicks RJ; O'Brien TJ J Nucl Med; 2013 Aug; 54(8):1270-7. PubMed ID: 23857513 [TBL] [Abstract][Full Text] [Related]
15. Cerebral benzodiazepine receptors in hippocampal sclerosis. An objective in vivo analysis. Koepp MJ; Richardson MP; Brooks DJ; Poline JB; Van Paesschen W; Friston KJ; Duncan JS Brain; 1996 Oct; 119 ( Pt 5)():1677-87. PubMed ID: 8931589 [TBL] [Abstract][Full Text] [Related]
16. In vivo measurement of hippocampal GABAA/cBZR density with [18F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsy. Vivash L; Gregoire MC; Bouilleret V; Berard A; Wimberley C; Binns D; Roselt P; Katsifis A; Myers DE; Hicks RJ; O'Brien TJ; Dedeurwaerdere S PLoS One; 2014; 9(1):e86722. PubMed ID: 24466212 [TBL] [Abstract][Full Text] [Related]
17. Clinical utility of flumazenil-PET versus [18F]fluorodeoxyglucose-PET and MRI in refractory partial epilepsy. A prospective study in 100 patients. Ryvlin P; Bouvard S; Le Bars D; De Lamérie G; Grégoire MC; Kahane P; Froment JC; Mauguière F Brain; 1998 Nov; 121 ( Pt 11)():2067-81. PubMed ID: 9827767 [TBL] [Abstract][Full Text] [Related]
18. Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI. A PET study of 44 patients. Hammers A; Koepp MJ; Richardson MP; Hurlemann R; Brooks DJ; Duncan JS Brain; 2003 Jun; 126(Pt 6):1300-18. PubMed ID: 12764053 [TBL] [Abstract][Full Text] [Related]
19. Clinical utility of 11C-flumazenil positron emission tomography in intractable temporal lobe epilepsy. Padma MV; Simkins R; White P; Satter M; Christian BT; Dunigan K; Lee C; Jacobs M; Mukherjee J; Mantil JC Neurol India; 2004 Dec; 52(4):457-62. PubMed ID: 15626833 [TBL] [Abstract][Full Text] [Related]